International Journal of Drug Policy 24 (2013) e91-98
Le fonctionnement de la prise en charge des patients séropositifs au Bénin, le cas de l’Atacora
International Journal of Infectious Diseases 80 (2019) 10–15
journal homepage: www.elsevier.com/locate/ijid
n this study, low-dose azithromycin did not meet the prespecified non-inferiority margin compared with standard-dose azithromycin in achieving clinical and serological cure in PCR-confirmed active yaws. Only a single participant (with presumed latent yaws) had definitive serological failure. This wo...rk suggests that 20 mg/kg of azithromycin is probably effective against yaws, but further data are needed.
more
Orientations provisoires
25 janvier 2020
Ce document est la première édition des orientations relatives aux stratégies de lutte anti-infectieuse à mettre en œuvre en cas de suspicion d’infection par un nouveau coronavirus (2019-nCoV). Il a été adapté du document de l’OMS intitulé P...révention et lutte contre les infections lors de la prise en charge de cas probables ou confirmés d’infection par le coronavirus du syndrome respiratoire du Moyen-Orient (MERS-CoV)(1), sur la base des connaissances actuelles de la situation en Chine et dans d’autres pays où des cas ont été identifiés, et de l’expérience acquise sur le syndrome respiratoire aigu sévère (SRAS)-CoV et le MERS-CoV (2).
more
ECDC Technical Report, Fourth Update 3 July 2020
Methicillin-resistant Staphylococcus aureus(MRSA) strainsor multidrug-resistant S.aureus, initially described in 1960s,emerged in the last decade as a cause of nosocomial infections responsible for rapidly progressive, potential fatal diseases including life-threatening pneumonia, necrotizing fascii...tis, endocarditis, osteomyelitis, severe sepsis, and toxinoses such as toxic shock syndrome. A multifactorial range of independent risk factors for MRSA has been reported in literature and include immunosuppression,hemodialysis, peripheral malperfusion, advanced age, extended in-hospital stays, residency in long-term care facilities (LTCFs), inadequacy of antimicrobial therapy,indwelling devices, insulin-requiring diabetes, and decubitusulcers, among others.
Hindawi Canadian Journal of Infectious Diseases and Medical Microbiology Volume 2019, Article ID 8321834, 9 pageshttps://doi.org/10.1155/2019/8321834
more
Haematologica has published European guidelines for empirical and targeted antibacterial therapy forfebrile neutropenic patients in the era of emerging resistance (ECIL-4). Indeed, collateral damage by broad-spectrum antibiotic therapy includes selection of multidrugresistant pathogens, and incr...eased predisposition to infec-tion by fungi and Clostridium difficile. Antibiotic resistance has become a major public health concern, with fears expressed that we will soon run out of antibiotics.
Haematologica December 2013 98: 1821-1825; doi:10.3324/haematol.2013.091769
more
Africa Centers for Disease Control and Prevention (Africa CDC) is aware of the media releases of the preliminary results of a large randomized clinical trial conducted in the United Kingdom, which included dexamethasone, a corticosteroid, as one of the drugs used for the treatment of COVID-19 patien...ts. The investigators reported that administration of oral or injectable dexamethasone resulted in about one-third reduction in mortality among COVID-19 patientsi that required mechanical ventilation and about one-fifth for patients requiring oxygen.
more
Short Version
This clinical practice guideline was developed in order to provide recommendations for the management of critically ill adult patients with COVID-19 in intensive care units (ICUs).
إن حول الإصدارات الإعلامية للنتائج الأولية للتجربة الإكلينيكية العشوائية ٍّتام) والتي تضمنت ديكساميثازون على إدراك Africa CDC المركز الأفريقي لمكافحة الأمراض و الوقاي...ة منها، UKالكبيرة التي أجريت في المملكة المتحدة () أفاد الباحثون بأن إعطاء ديكساميثازون ۱وكورتيكوستيرويد كإحدى أذرع العلاج.(عن طريق الفم أو عن طريق الحقن أدى إلى انخفاض حوالي ثلث الوفيات بين الذين يحتاجون إلى i]COVID-19المرضى المصابين بفيروس كورونا المستجد [َّتهوية ميكانيكية وحوالي الخمس للمرضى الذين يحتاجون إلى الأكسجين. إنا مدرج في قائمة الأدوية الأساسية ًديكساميثازون هو دواء عام وغير مكلف نسبيإفريقيا.لمنظمة الصحة العالمية ويستخدم على نطاق واسع في
more
DOI:https://doi.org/10.1016/S2213-2600(20)30316-7
The Lancet Respiratory Medicine
It is intended for use among clinicians taking care of moderate to severe COVID-19 cases.
The COVID-19 outbreak has brought with it the need for improved critical care for patients who develop severe disease. The majority of COVID-19 patients present with mild to moderate illness, 15% develop sever...e illness and about 5% develop critical conditions needing intensive care unit (ICU) care, requiring noninvasive or invasive ventilation
more
AIIMS/ ICMR-COVID-19 National Task Force/Joint Monitoring Group. Flow Chart, 19 May 2021